In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade.
Saved in:
| Title: | In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade. |
|---|---|
| Authors: | Lee CYC; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom.; Cellular Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., Dean I; Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom., Richoz N; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom., Li Z; Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom., Kennedy BC; Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.; NDM Centre for Immuno-Oncology, University of Oxford, Oxford, United Kingdom., Vettore LA; Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.; NDM Centre for Immuno-Oncology, University of Oxford, Oxford, United Kingdom., Samarakoon Y; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom., Gilroy KL; Cancer Research UK Scotland Institute, Glasgow, United Kingdom., Hasegawa T; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom., Carlesso G; Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Hammond SA; Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Dovedi SJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Sansom OJ; Cancer Research UK Scotland Institute, Glasgow, United Kingdom., Tuong ZK; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom.; Cellular Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., Halim TYF; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom., Withers DR; Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.; NDM Centre for Immuno-Oncology, University of Oxford, Oxford, United Kingdom., Clatworthy MR; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom.; Cellular Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom. |
| Source: | Cancer immunology research [Cancer Immunol Res] 2025 Sep 02; Vol. 13 (9), pp. 1453-1470. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
